On May 14, 2025, the US Food and Drug Administration (FDA) approved belzutifan for adults and children over 12 years of age, who have pheochromocytoma (pheo) or paraganglioma (para) that has spread to nearby tissues, metastasized, not able to be removed surgically, or unable to be cured through other treatment options.
The data from the clinical trial, that led to FDA approval, will be presented at the ESMO Conference in mid-October by Dr. Camilo Jimenez. This education webinar will be the first time this data is shared with the patient population.
Registration for this webinar has closed. Watch the recording here!
See below for more info on the FDA approval announcement in May.
